Arrogene, Inc., incorporated in 2007, is working on building a pipeline of new nano-medicines capable of targeting cancer cells and specifically preventing tumor growth.
Mission is to commercialize both a new targeted cancer treatment technology and a proprietary molecular delivery platform that interferes with those targets in order to inhibit and finally stop, tumor progression.
Black Light Surgical (BLS), Inc. has developed a medical device that has shown a very high level of sensitivity and specificity in determining in a matter of seconds whether a brain lesion is benign or cancerous, and can provide tools to aid surgeons in achieving complete resection of tumors.
BLS will primarily focus on use of optical technologies to provide intra-operative real-time diagnostic information to surgeons. The technology is now being developed to apply to dermatologic, breast and other lesions.
Developed at Cedars-Sinai, Fortem Neurosciences, Inc. has 3 platform technologies for the treatment of Alzheimer’s and dementia.
This year, Alzheimer’s and other dementias will cost the nation an estimated $230 billion. By 2050, that number could rise to more than $1 trillion.
Hydrophilix, Inc. was spun-out of the University of California, Los Angeles based on the Hydrophilix coating technology, a direct result of federal, state, and local support. The proof-of-concept began with basic research funding from the National Science Foundation Sustainable Chemistry Program and fellowships for individual scholars. The technology was further developed for commercial application, propelled with seed funding from the NSF Clean Energy for Green Industry, UCLA’s Physical Sciences Entrepreneurship and Innovation Fund, and private investment.
LongLifeRx, Inc. was formed to develop and commercialize technology based on the research being done at UCLA for extending the years of good health, rather than just living longer.
Analogues are being developed specifically for slowing the aging process and age-related diseases such as heart disease, dementia, kidney failure and other cancers.
Rather than just living longer, the technology holds promise for extending the years of good health.
The company is planning both a natural supplement launch as well as developing analogues that require FDA approval.
Nanotech Energy, Inc., was formed in 2014 to move the world’s leading-edge research on graphene-based energy storage devices from the laboratory to the marketplace.
Imagine a world where you could charge your smart phone in just seconds. Same goes for laptops, power tools, medical devices, even electric cars. And then imagine that instead of traditional batteries that run out of juice very quickly, you used long-lasting energy storage systems that can last three times longer on a single charge. These are some of the goals of Nanotech Energy, Inc.
Novonco Therapeutics, Inc.'s three platform technologies represent the next generation of cancer therapies, offering hope to patients with limited treatment options, including those with acute myelogenous, leukemia, ovarian, breast, pancreatic, lung, prostate, liver and other cancers. Novonco is working to help transform care from one-size-fits-all treatments to therapies that are personalized to the patient.
Founded in 2006, Orbsen Therapeutics, Ltd. is developing ground-breaking new treatments for some of today’s most challenging diseases. Utilizes new technologies based on stromal cell therapy to promote tissue repair. Orbsen’s stromal cell technology has significant advantages over others: cost and scalability, efficacy, anti-inflammatory effect.
Partnered with 25 global leaders in stromal cell therapy for the validation, development and commercialization of products in a number of fields, including Crohn's Disease, Lupus, Primary Sclerosing Cholangitis, Rheumatoid arthritis, autoimmune and inflammatory conditions.
SuperMetalix, Inc., was formed to commercialize the cutting-edge science in super-hard metals being undertaken by Dr. Richard B. Kaner and his colleagues at UCLA’s Kaner Laboratory. Through proprietary formulas developed at the Kaner Lab, SuperMetalix has created cost-efficient super-hard metal.Supermetalix aims to revolutionize the market by producing cost-efficient, superhard metallic compounds far superior to today’s commonly used hard-materials.
Amplify is an AI powered conversation platform for businesses. Proprietary technology enables marketers and enterprises to generate real conversations and actionable outcomes using the TruVerse platform.
Combination of machine learning and human experts to continuously grow more intelligent and optimize every conversation.
Platform allows hyper-segmentation and can plug directly into a company’s CRM or DMP systems.
Vault Nano, Inc. d.b.a. Vault Pharma is a therapeutic drug company with a technology platform based on the vault particle discovered in a UCLA lab.
Westwood Bioscience, Inc. was founded to commercialize the “silicasome” technology, developed in UCLA labs, addressing inherent problems with liposomes, a multi-billion dollar market, developed decades ago as a carrier mechanism to deliver therapeutics to targeted cells.
Silicasome’s are expected to provide improved stability, drug loading, treatment efficacy and toxicity reduction.
Options for cancer therapy compared with profitable liposomes formulations, introducing a novel encapsulated nano-carriers as a treatment platform for pancreatic, colon and other forms of cancer.
Triller is an AI-powered music video app and talent discovery platform that allows users to create professional-looking videos in a matter of seconds.
Pick a song, select the portion of the song you want to use, snap a few takes and with the tap of a button you have a celebrity-quality music video starring you and your friends. Triller relies solely on organic growth and has more than 23 million downloads, with celebrities from Kevin Hart to Vanessa Hudgens regularly using the app to create their own music videos. Triller is currently raising $200 million at a $1.25 billion pre-money valuation, with plans to expand its AI technology and develop the brand as a talent discovery platform.
The holdings identified do not represent all of the securities purchased, sold, or recommended for the Fund. It should not be assumed that recommendations made in the past or the future will be profitable. Past performance does not guarantee future results.